Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Manifold Bio has advanced its multiplexed in vivo screening and AI-guided protein design platform to generate novel, tissue-targeted biologics, with CNS (neurodegenerative) and peripheral delivery programs currently in preclinical development. Initial internal programs target CNS diseases such as Alzheimer's and Parkinson's using advanced delivery of mAbs and oligonucleotides. No clinical readouts yet released; preclinical proof-of-concept shows massively parallel protein tracking and improved tissue targeting.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Manifold Bio.